Nonetheless, recombinant ADAMTS-13 substitution may prospectively serve as a promising therapeutic intervention in patients with CHD, as ADAMTS-13 replacement therapy is currently under investigation for hereditary TTP and several other conditions, such as infection, myocardial infarction and thrombotic microangiopathy [8,9]. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.